Amplia Therapeutics Ltd (ASX: ATX) Share Price and News
Price
$0.06
Movement
0.003 (+5.26%)
as at 12 Jun - Closed (20 mins delayed)
52 Week Range
$0.049 - $0.1765
1 Year Return
-16.14%
Amplia Therapeutics Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$23.28 million
P/E Ratio
N/A
Dividend Yield
0.00%
Shares Outstanding
387.95 million
Earnings per share
-0.021
Dividend per share
N/A
Year To Date Return
-35.96%
Earnings Yield
N/A
Franking
-
Share Price
$0.06
Day Change
0.003 (+5.26%)
52 Week Range
$0.049 - $0.1765
Yesterday's Close
$0.057
Today's Open
$0.057
Days Range
$0.057 - $0.06
Volume
224,063
Avg. Volume (1 month)
4,413,396
Turnover
$13,277
as at 12 Jun - Closed
Amplia Therapeutics Ltd (ASX: ATX)
Latest News
Healthcare Shares
2 ASX biotech shares rocketing more than 40% on big news
Share Market News
Why the Amplia (ASX:ATX) share price is rocketing 41% higher today
Share Market News
Here's why the Amplia (ASX:ATX) share price is up 9% today
Share Market News
Amplia Therapeutics share price up 16% in 2 days as former Macquarie CEO takes substantial stake
Share Market News
US congressman resigns over ASX insider trading penny stock scandal
Share Market News
ASX Watergate Arrest: The alleged insider trading at Innate Immunotherapeutics Ltd (ASX:IIL)
Investing
Cann Group Ltd is one of 64 new shares added to the All Ordinaries this quarter
Investing
Were these the 3 worst shares on the ASX in 2017?
Investing
These are the 5 biggest losers on the All Ordinaries in the last 12 months
Investing
One crucial thing to consider before investing in risky biotech shares
Investing
The 3 biggest investing mistakes you can make
Investing
Here's how to get rich quick (and stay poor forever)
1❯
ATX ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| 30th May 2025 2025-05-30T15:14:30 | Appendix 4G - Key to Corporate Governance Disclosures | YesNo | 3:14pm | 14 | 303k |
| 30th May 2025 2025-05-30T15:14:21 | 2025 Corporate Governance Statement | YesNo | 3:14pm | 16 | 358k |
| 30th May 2025 2025-05-30T15:13:25 | Preliminary Final Report and Annual Report YE 31 March 2025 | YesNo | 3:13pm | 71 | 20M |
| 16th May 2025 2025-05-16T17:05:25 | Change in substantial holding | YesNo | 5:05pm | 5 | 194k |
| 15th May 2025 2025-05-15T08:21:39 | ACCENT Trial Achieves Superiority over Chemotherapy Alone | YesNo | 8:21am | 2 | 185k |
| 12th May 2025 2025-05-12T08:20:14 | Amplia Appoints Dr Jason Lickliter as Chief Medical Officer | YesNo | 8:20am | 2 | 175k |
| 30th Apr 2025 2025-04-30T08:28:58 | Quarterly Activities/Appendix 4C Cash Flow Report | YesNo | 8:28am | 7 | 316k |
| 28th Apr 2025 2025-04-28T10:24:55 | ACCENT Data Update Presented at International Conference | YesNo | 10:24am | 4 | 2M |
| 9th Apr 2025 2025-04-09T08:20:17 | US Clinical Trial Activities for Narmafotinib Now Underway | YesNo | 8:20am | 3 | 180k |
| 27th Mar 2025 2025-03-27T08:15:40 | Encouraging Updated Data from Pancreatic Cancer Trial | YesNo | 8:15am | 2 | 177k |
About Amplia Therapeutics Ltd
Amplia Therapeutics Ltd is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. Its molecule, AMP945 is a pure-play inhibitor, while the second molecule, AMP886, is a multi-action molecule that hits two other important cancer pathways: VEGFR3 and FLT3.
ATX Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 11 Jun 2025 | $0.06 | $0.00 | 0.00% | 287,000 | $0.06 | $0.06 | $0.06 |
| 10 Jun 2025 | $0.06 | $-0.01 | -15.15% | 2,617,501 | $0.07 | $0.07 | $0.06 |
| 06 Jun 2025 | $0.07 | $0.00 | 0.00% | 2,020,110 | $0.06 | $0.07 | $0.06 |
| 05 Jun 2025 | $0.06 | $0.01 | 20.00% | 8,746,743 | $0.05 | $0.06 | $0.05 |
| 04 Jun 2025 | $0.05 | $0.00 | 0.00% | 801,194 | $0.05 | $0.05 | $0.05 |
| 03 Jun 2025 | $0.05 | $0.00 | 0.00% | 302,069 | $0.05 | $0.05 | $0.05 |
| 02 Jun 2025 | $0.05 | $0.00 | 0.00% | 609,155 | $0.05 | $0.05 | $0.05 |
| 30 May 2025 | $0.05 | $0.00 | 0.00% | 404,604 | $0.05 | $0.05 | $0.05 |
| 29 May 2025 | $0.05 | $0.00 | 0.00% | 1,481,435 | $0.05 | $0.05 | $0.05 |
| 28 May 2025 | $0.05 | $0.00 | 0.00% | 1,019,262 | $0.05 | $0.05 | $0.05 |
| 27 May 2025 | $0.05 | $0.00 | 0.00% | 1,834,613 | $0.05 | $0.05 | $0.05 |
| 26 May 2025 | $0.05 | $0.00 | 0.00% | 249,662 | $0.05 | $0.05 | $0.05 |
| 23 May 2025 | $0.05 | $0.00 | 0.00% | 1,975,453 | $0.05 | $0.05 | $0.05 |
| 22 May 2025 | $0.05 | $0.00 | 0.00% | 293,415 | $0.05 | $0.05 | $0.05 |
| 21 May 2025 | $0.05 | $0.00 | 0.00% | 826,457 | $0.05 | $0.05 | $0.05 |
| 20 May 2025 | $0.05 | $0.00 | 0.00% | 2,567,590 | $0.05 | $0.05 | $0.05 |
| 19 May 2025 | $0.05 | $-0.01 | -15.38% | 8,869,769 | $0.06 | $0.06 | $0.05 |
| 16 May 2025 | $0.07 | $-0.01 | -14.29% | 5,437,807 | $0.07 | $0.07 | $0.06 |
| 15 May 2025 | $0.07 | $0.02 | 36.36% | 56,028,459 | $0.07 | $0.10 | $0.07 |
| 14 May 2025 | $0.06 | $0.00 | 0.00% | 66,427 | $0.05 | $0.06 | $0.05 |
| 13 May 2025 | $0.05 | $0.00 | 0.00% | 591,958 | $0.06 | $0.06 | $0.05 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 20 Dec 2024 | Robert Peach | Issued | 815,218 | $67,663 |
As advised by the company. Participation in Capital Raise
|
| 20 Dec 2024 | Robert Peach | Issued | 1,086,957 | $125,000 |
As advised by the company. Participation in Capital Raise
|
| 20 Dec 2024 | Jane Bell | Issued | 521,739 | $43,304 |
As advised by the company. Participation in Capital Raise
|
| 20 Dec 2024 | Jane Bell | Issued | 695,652 | $79,999 |
As advised by the company. Participation in Capital Raise
|
| 20 Dec 2024 | Warwick Tong | Transfer | 661,107 | $54,871 |
Off-market transfer. Assuming off market transfer of shares
|
| 20 Dec 2024 | Warwick Tong | Transfer | 661,107 | $54,871 |
Off-market transfer. Assuming off market transfer of shares
|
| 20 Dec 2024 | Warwick Tong | Issued | 521,739 | $43,304 |
As advised by the company. Participation in Capital Raise
|
| 20 Dec 2024 | Warwick Tong | Issued | 695,652 | $79,999 |
As advised by the company. Participation in Capital Raise
|
| 20 Dec 2024 | Christopher Burns | Issued | 347,826 | $39,999 |
As advised by the company. Participation in Capital Raise
|
| 20 Dec 2024 | Christopher Burns | Issued | 260,869 | $21,652 |
As advised by the company. Participation in Capital Raise
|
| 26 Aug 2024 | Christopher Burns | Issued | 586,321 | $36,351 |
Employee Share Ownership Plan.
|
| 19 Jun 2024 | Robert Peach | Buy | 827,268 | $45,499 |
Off-market trade.
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Mr Andrew John Cooke | Company Secretary | Oct 2013 |
Mr Cooke has experience in law, corporate finance, governance and compliance. As a Non-Executive Director and Company Secretary of a number of ASX listed companies he has over 25 years of boardroom experience and has developed a practical blend of legal and commercial acumen. He has served as a consultant to listed, public and private companies in the resources, property and biotech sectors focussing on stock exchange and regulatory compliance and a wide range of corporate transactions. Andrew has been the Company Secretary since 11 October 2013.
|
| Dr Robert Peach | Non-Executive Director | Sep 2015 |
Dr Peach has over 30 years of drug discovery and development experience in the Pharmaceutical and Biotechnology industry. Dr Peach held senior executive and scientific positions in other companies including Apoptos, Biogen Idec, IDEC and Bristol-Myers Squibb, supporting in-licensing, acquisition and venture investments. His drug discovery and development experience in autoimmune and inflammatory diseases, and cancer has resulted in multiple drugs entering clinical trials and 3 registered drugs. He is also member of Risk Committee.
|
| Ms Jane Catherine Bell | Non-Executive Director | Apr 2021 |
Ms Bell has more than 30 years of experience in leading law firms, financial services and corporate treasury operations gained living in Melbourne, London, Toronto, San Francisco and Brisbane. Ms Bell has been a non-executive director since 2002, serving on 17 boards including public and private hospitals, biotechnology, medical research and funds management boards. He is also Chair of Risk Committee.
|
| Dr Warwick Bonner Tong | Non-Executive DirectorNon-Executive Chairman | May 2018 |
Dr Tong has more than 30 years of experience in the Pharmaceutical and Biotechnology industry. After his early career in General Medical Practice, Dr Tong has held a wide variety of roles in the pharmaceutical and biotech industry in NZ (Glaxo) Singapore (GlaxoWellcome) London (GSK), Boston (Surface Logix) and Melbourne (CTx Cancer Therapeutics CRC). His roles have included Medical Director, Regional Business Development Director (Asia Pacific), Commercial Strategy Director (International) and SVP Development (USA). Dr Tong is also a member of the Risk Committee.
|
| Dr Christopher John Burns | Chief Executive OfficerManaging Director | May 2018 |
Dr Burns is a drug discovery leader having worked in various roles in pharma, biotech and academia for over 30 years. After 5 years he returned to Australia as a Research Fellow at the University of Sydney with the CRC for Molecular Engineering and Technology and after two years moved to the biotechnology company Ambri as Head of Chemistry. Chris then moved to the Melbourne-based biotech Cytopia as Head of Medicinal Chemistry and later as Research Director.
|
| Tim Luscombe | Chief Financial Officer |
-
|
|
| Rhiannon Jones | Chief Operating Officer |
-
|
|
| Jose Iglesias | Clinical Adviser (Oncology) |
-
|
|
| Nicole Kruger | Director Clinical Operations |
-
|
|
| Charlotte Mulder | Director Early Clinical Development |
-
|
|
| Terrie-Anne Cock | Director Translational Science |
-
|
|
| Paul Timpson | FAK Biology Adviser |
-
|
|
| Margaret Frame | FAK Biology Adviser |
-
|
|
| Adrian Sulistio | Manager Product Development |
-
|
|
| Jason Lickliter | Medical Adviser |
-
|
|
| Mark Devlin | Scientific Adviser |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| HSBC Custody Nominees (Australia) Limited | 52,609,304 | 19.37% |
| BNP Paribas Noms Pty Ltd | 21,612,234 | 7.96% |
| Bond Street Custodians Limited (LAM1 D08047 A/C) | 18,861,500 | 6.94% |
| Citicorp Nominees Pty Limited | 7,911,702 | 2.91% |
| Ubs Nominees Pty Ltd | 6,641,084 | 2.45% |
| Elk River Holdings Pty Ltd | 4,885,323 | 1.80% |
| CTXT Pty Ltd | 3,940,579 | 1.45% |
| Dr Robert Peach | 3,564,765 | 1.31% |
| Christopher John Burns | 3,134,470 | 1.15% |
| HEH Enterprises Pty Ltd (HEH Enterprises Invest A/C) | 3,102,500 | 1.14% |
| M A Whiting and T A Whiting (Whiting Family S/F A/C) | 3,083,510 | 1.14% |
| Dr Warwick Tong | 3,016,247 | 1.11% |
| Mrs Jane Bell | 2,835,664 | 1.04% |
| Mr Anthony Hamilton Martin | 2,820,323 | 1.04% |
| J & J Stuart Pty Ltd (Stuart Family Super A/C) | 2,700,000 | 0.99% |
| Ravinna Pty Ltd (Ravinna A/C) | 2,626,105 | 0.97% |
| Mrs Sharon Lewis | 2,430,000 | 0.89% |
| GP Securities Pty Ltd | 2,412,500 | 0.89% |
| Mr Nicholas Dermott McDonald | 2,216,673 | 0.82% |
| 34th Avenue Pty Ltd (Devlin Family A/C) | 2,215,237 | 0.82% |